RxDoctor Payments DataLook up a doctor →

Kenel Fernandez Barbosa, MD

Hematology & Oncology · Bayamon, PRNPI 1104919166

Payments from drug & device makers

$23,829in general payments, 2019–2025

Across 1,030 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Johnson & Johnson$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Genentech USA, Inc.$2K
  • Merck$2K
  • PBG Puerto Rico LLC$1K
  • plus $10K from 42 others

What the payments were for

  • Food & beverage$22,53495%
  • Education$1,2955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,829 in reported general payments places this provider in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$579,768
Medicare patients
51
Services billed
12,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib59$941,957
XtandiEnzalutamide52$736,310
TagrissoOsimertinib Mesylate44$728,766
PomalystPomalidomide24$552,465
SprycelDasatinib26$471,809
ErleadaApalutamide27$401,848
Abiraterone Acetate178$329,377
VerzenioAbemaciclib14$217,688
ZytigaAbiraterone Acetate17$182,504
ImbruvicaIbrutinib12$145,953
GleevecImatinib Mesylate13$97,660
BosulifBosutinib13$63,586
Imatinib Mesylate35$45,497
RetacritEpoetin Alfa-Epbx28$27,500
Exemestane101$15,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Bosulif, Retacrit$201$1,033,043100 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$2,590$1,024,27450 claims
Astellas Pharma US IncXtandi$134$736,31052 claims
AstraZenecaTagrisso$3,254$728,76644 claims
Johnson & JohnsonErleada, Zytiga, Xarelto$3,101$598,44960 claims
Lilly USA, LLCVerzenio$15$217,68814 claims
NovartisGleevec$1,009$97,66013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →